title: Life after a ventricular arrhythmia.
abstract: BACKGROUND
  There are few data from community-based evaluations of outcomes after a life-threatening ventricular arrhythmia (LTVA). We evaluated patients' quality of life (QOL) and medical costs after hospitalization and treatment for their first episode of an LTVA.
  
  
  METHODS
  We prospectively evaluated QOL by use of the Duke Activity Status Index (DASI), Medical Outcomes Study SF-36 mental health and vitality scales, the Cardiac Arrhythmia Suppression Trial (CAST) symptom scale, and resource use in patients discharged after a first episode of an LTVA in a managed care population of 2.4 million members.
  
  
  RESULTS
  We enrolled 264 subjects with new cases of LTVA. Although functional status initially decreased compared with self-reports of pre-event functional status, both functional status and symptom levels improved significantly during the study period. These improvements were greater in patients receiving an implantable cardioverter defibrillator (ICD) than in patients receiving amiodarone. Ratings of mental health and vitality were not significantly different between the treatment groups and did not change significantly during follow-up. The total 2-year medical costs were higher for patients receiving an ICD than for patients receiving amiodarone, despite lower costs during the follow-up period for the patients receiving an ICD.
  
  
  CONCLUSIONS
  New onset of an LTVA has a substantial negative initial impact on QOL. With therapy, most patients have improvements in their QOL and symptom level, possibly more so after treatment with an ICD. The costs of treating these patients are very high.
authors.affiliation: Division of Research, Kaiser Permanente, Oakland, Calif 94611-5714, USA. jth@dor.kaiser.org
authors.forename: John
authors.initials: J
authors.lastname: Hsu
authors.forename: Connie
authors.initials: C
authors.lastname: Uratsu
authors.forename: Alison
authors.initials: A
authors.lastname: Truman
authors.forename: Charles
authors.initials: C
authors.lastname: Quesenberry
authors.forename: Kathryn M
authors.initials: KM
authors.lastname: McDonald
authors.forename: Mark A
authors.initials: MA
authors.lastname: Hlatky
authors.forename: Joe
authors.initials: J
authors.lastname: Selby
mesh_terms: D000368:Aged; D000638:Amiodarone / Q000191:economics / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000191:economics / Q000627:therapeutic use; D017147:Defibrillators, Implantable / Q000191:economics / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D017048:Health Care Costs; D006304:Health Status; D006323:Heart Arrest / Q000628:therapy; D006760:Hospitalization / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology; D017180:Tachycardia, Ventricular / Q000191:economics / Q000523:psychology / Q000628:therapy*; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000191:economics / Q000523:psychology / Q000628:therapy*
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone